Published in J Clin Oncol on October 01, 2005
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol (2012) 4.48
New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol (2010) 1.80
Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg (2012) 1.55
Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc (2012) 1.36
Clinical significance of lymph node metastasis in gastric cancer. World J Gastroenterol (2014) 1.25
The impact of a high body mass index on laparoscopy assisted gastrectomy for gastric cancer. Surg Endosc (2009) 1.21
D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol (2012) 1.11
Combining the negative lymph nodes count with the ratio of positive and removed lymph nodes can better predict the postoperative survival in cervical cancer patients. Cancer Cell Int (2013) 1.05
Lymph node metastasis of gastric cancer. Cancers (Basel) (2011) 1.02
Stage-stratified analysis of prognostic significance of tumor size in patients with gastric cancer. PLoS One (2013) 1.01
Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg (2007) 0.95
Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer (2006) 0.94
Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford) (2011) 0.91
Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5. J Pediatr Surg (2012) 0.91
Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy. Surg Endosc (2015) 0.91
Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield. J Gastrointest Surg (2015) 0.89
Extended lymphadenectomy improvement of overall survival of gastric cancer patients with perigastric node metastasis. Langenbecks Arch Surg (2011) 0.89
Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol (2013) 0.89
Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy. Int J Surg Oncol (2012) 0.89
Surgeons' knowledge of quality indicators for gastric cancer surgery. Gastric Cancer (2007) 0.88
Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford) (2012) 0.88
Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. World J Gastroenterol (2014) 0.88
Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC Cancer (2012) 0.88
Impact of lymph node micrometastasis on gastric carcinoma prognosis: a meta-analysis. World J Gastroenterol (2015) 0.87
Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer. Am J Cancer Res (2014) 0.87
Necessity of harvesting at least 25 lymph nodes in patients with stage N2-N3 resectable gastric cancer: a 10-year, single-institution cohort study. Medicine (Baltimore) (2015) 0.85
Methylation of CpG sites in RNF180 DNA promoter prediction poor survival of gastric cancer. Oncotarget (2014) 0.85
Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. J Am Coll Surg (2015) 0.85
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer (2010) 0.84
Ratio between negative and positive lymph nodes is suitable for evaluation the prognosis of gastric cancer patients with positive node metastasis. PLoS One (2012) 0.83
Negative node count improvement prognostic prediction of the seventh edition of the TNM classification for gastric cancer. PLoS One (2013) 0.82
Metastatic lymph node ratio: a new staging system for gastric cancer. World J Surg (2009) 0.82
Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. Clin Exp Metastasis (2012) 0.82
Prognostic impact of dissected lymph node count on patients with node-negative gastric cancer. World J Gastroenterol (2009) 0.82
Impact of lymph node ratio as a valuable prognostic factor in gallbladder carcinoma, focusing on stage IIIB gallbladder carcinoma. J Korean Surg Soc (2013) 0.82
Clinical significance of accurate identification of lymph node status in distant metastatic gastric cancer. Oncotarget (2015) 0.82
Treatment and outcomes of gastric cancer among United States-born and foreign-born Asians and Pacific Islanders. Cancer (2009) 0.82
Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surg Today (2014) 0.81
Prognostic significance of distal subtotal gastrectomy with standard D2 and extended D2 lymphadenectomy for locally advanced gastric cancer. Sci Rep (2015) 0.81
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. Urology (2010) 0.81
Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). Urol Oncol (2016) 0.81
The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Can Urol Assoc J (2016) 0.80
The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer (2015) 0.80
Impact of the number of dissected lymph nodes on survival for gastric cancer after distal subtotal gastrectomy. Gastroenterol Res Pract (2011) 0.80
Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30 years. World J Surg Oncol (2014) 0.79
The metastasis suppressor SOX11 is an independent prognostic factor for improved survival in gastric cancer. Int J Oncol (2014) 0.79
Bursectomy and non-bursectomy D2 gastrectomy for advanced gastric cancer, initial experience from a single institution in China. World J Surg Oncol (2015) 0.79
Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biol Med (2015) 0.78
Adequacy of lymph node retrieval for ampullary cancer and its association with improved staging and survival. World J Surg (2013) 0.78
Lymph node dissection for gastric cancer: a critical review. Oncol Rev (2012) 0.77
Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy. J Cancer Res Clin Oncol (2014) 0.77
Robot-assisted gastrectomy for early gastric cancer: is it beneficial in viscerally obese patients compared to laparoscopic gastrectomy? World J Surg (2015) 0.77
The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter. Open Biol (2014) 0.77
Self-reported experience and outcomes of care among stomach cancer patients at a median follow-up time of 27 months from diagnosis. Support Care Cancer (2007) 0.77
Clinical significance of medial approach for suprapancreatic lymph node dissection during laparoscopic gastric cancer surgery. Surg Endosc (2014) 0.77
Applicability of the methylated CpG sites of paired box 5 (PAX5) promoter for prediction the prognosis of gastric cancer. Oncotarget (2014) 0.77
Digestive cancer surgery in the era of sentinel node and epithelial-mesenchymal transition. World J Gastroenterol (2013) 0.76
The role of lymph nodes in predicting the prognosis of ampullary carcinoma after curative resection. World J Surg Oncol (2015) 0.75
A new predictive model combined of tumor size, lymph nodes count and lymphovascular invasion for survival prognosis in patients with lymph node-negative gastric cancer. Oncotarget (2016) 0.75
Determining the optimal number of lymph nodes harvested during esophagectomy. J Gastrointest Oncol (2016) 0.75
Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomes. Ann Med Surg (Lond) (2016) 0.75
Laparoscopy-assisted resection of proximal gastric cancer: is less than all more or less complete, or is all more, nonetheless? Gastric Cancer (2013) 0.75
Prognostic Discrepancy of the 6th and 7th UICC N Classification for Lymph Node Staging in Gastric Cancer Patients after Curative Resection. Case Rep Oncol (2017) 0.75
Racial and ethnic disparities in gastric cancer outcomes: more important than surgical technique? World J Gastroenterol (2014) 0.75
Effect of lymphadenectomy extent on advanced gastric cancer located in the cardia and fundus. World J Gastroenterol (2008) 0.75
The Ratio-Based N Staging System Can More Accurately Reflect the Prognosis of T4 Gastric Cancer Patients with D2 Lymphadenectomy Compared with the 7th American Joint Committee on Cancer/Union for International Cancer Control Staging System. J Gastric Cancer (2016) 0.75
D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Med (2016) 0.75
Does the retrieval of at least 15 lymph nodes confer an improved survival in patients with advanced gastric cancer? J Gastric Cancer (2014) 0.75
Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer? Ann Surg Treat Res (2014) 0.75
Does a Higher Cutoff Value of Lymph Node Retrieval Substantially Improve Survival in Patients With Advanced Gastric Cancer?-Time to Embrace a New Digit. Oncologist (2016) 0.75
Is postoperative chemoradiotherapy benefit to D2-resected gastric cancer? Transl Gastroenterol Hepatol (2016) 0.75
Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database. HPB (Oxford) (2015) 0.75
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. Urology (2011) 0.75
Alternative staging of regional lymph nodes in gastric cancer. Prz Gastroenterol (2016) 0.75
Influence of negative lymph node in No 7 on survival of patients with middle thoracic esophageal squamous cell carcinoma. Onco Targets Ther (2016) 0.75
The number of retrieved lymph nodes needed for accurate staging differs based on the presence of preoperative chemoradiation for rectal cancer. Medicine (Baltimore) (2016) 0.75
Impact on long-term survival of the number of lymph nodes resected in patients with pT1N0 gastric cancer after R0 resection: A multicenter study in China. Medicine (Baltimore) (2016) 0.75
Extended lymphadenectomy in gastric cancer is crucial. World J Surg (2013) 0.75
The positive impact of surgeon specialization on survival for gastric cancer patients after surgery with curative intent. Gastric Cancer (2014) 0.75
A High Lymph Node Yield is Associated with Prolonged Survival in Elderly Patients Undergoing Curative Gastrectomy for Cancer: A Dutch Population-Based Cohort Study. Ann Surg Oncol (2017) 0.75
Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer. J Cancer (2017) 0.75
Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Langenbecks Arch Surg (2016) 0.75
One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation (2011) 1.98
Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sites. J Am Coll Surg (2005) 1.45
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol (2005) 1.45
Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biol Ther (2010) 1.44
Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol (2010) 1.31
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res (2004) 1.29
Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest (2008) 1.20
The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol (2011) 1.17
PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther (2013) 1.01
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis (2013) 1.01
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem (2012) 1.00
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther (2012) 0.99
Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat Rev Urol (2011) 0.98
Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up. Ann Surg Oncol (2014) 0.97
Androgen receptor blockade in experimental combination therapy of pancreatic cancer. J Surg Res (2007) 0.94
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res (2012) 0.92
Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? J Am Coll Surg (2002) 0.92
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer (2011) 0.90
AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma. HPB (Oxford) (2010) 0.89
Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp Cell Res (2005) 0.89
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Int J Oncol (2013) 0.88
Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. J Surg Res (2012) 0.88
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol (2013) 0.87
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One (2012) 0.87
Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol (2012) 0.86
Gastric adenomyoma: definitely benign or defiantly premalignant? Dig Dis Sci (2005) 0.86
Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol (2005) 0.85
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. HPB (Oxford) (2011) 0.85
A comparison of five competing lymph node staging schemes in a cohort of resectable gastric cancer patients. Ann Surg Oncol (2013) 0.84
Collision tumor in form of primary adenocarcinoma and neuroendocrine carcinoma of the duodenum. Rare Tumors (2012) 0.84
Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Cancer Chemother Pharmacol (2010) 0.84
Pathologic response to preoperative therapy: does it mean what we think it means? Ann Surg Oncol (2009) 0.83
Rare hepatic arterial anatomic variants in patients requiring pancreatoduodenectomy and review of the literature. Case Rep Surg (2012) 0.83
Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Mol Cancer Ther (2014) 0.83
Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One (2013) 0.83
Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens. J Surg Res (2007) 0.82
Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis. Hepatogastroenterology (2013) 0.82
Molecular mechanisms for individualized cancer care. J Am Coll Surg (2008) 0.82
Factors influencing perioperative blood transfusions in patients with gastrointestinal cancer. J Surg Res (2007) 0.81
AHPBA/SSO/SSAT sponsored consensus conference on the multidisciplinary treatment of colorectal cancer metastases. HPB (Oxford) (2013) 0.80
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res (2013) 0.80
Routine nasogastric decompression is unnecessary after pancreatic resections. Arch Surg (2012) 0.80
Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy. Ann Surg Oncol (2003) 0.79
Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol (2011) 0.79
Impact of pre-existing type-2 diabetes on patient outcomes after radical resection for gastric cancer: a retrospective cohort study. Dig Dis Sci (2013) 0.79
Defining palliation in patients undergoing gastrectomy for gastric cancer. J Am Coll Surg (2004) 0.78
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res (2007) 0.78
Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II. PLoS One (2012) 0.78
Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Radiat Oncol (2011) 0.77
Chemosensitization by fibroblast growth factor-2 is not dependent upon proliferation, S-phase accumulation, or p53 status. Biochem Pharmacol (2002) 0.77
Extrahepatic bile duct stricture and elevated CA 19-9: malignant or benign? South Med J (2003) 0.77
Extended left-sided pancreatectomy with spleen preservation. J Surg Oncol (2008) 0.76
Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer. HPB (Oxford) (2009) 0.76
The real estate of gastric cancer induction therapy: location versus intrinsic molecular architecture. Ann Surg Oncol (2012) 0.75
Resection of type I gastric carcinoid: when and why? J Surg Res (2010) 0.75
Intraduodenal sarcoma recurrence of retroperitoneal origin: an unusual cause for a duodenal obstruction. World J Surg Oncol (2012) 0.75
Laparoscopy-assisted resection of proximal gastric cancer: is less than all more or less complete, or is all more, nonetheless? Gastric Cancer (2013) 0.75
Is timing to delivery of treatment a reliable measure of quality of care for patients with colorectal adenocarcinoma? Surgery (2013) 0.75
Pancreatoduodenectomy with or without pyloric preservation: a clinical outcomes comparison. HPB Surg (2009) 0.75
Obesity and postgastrectomy outcomes: large risks, fat chances, or no big deal? Gastric Cancer (2012) 0.75
More on: what's in a name, of and around the pancreas? J Gastrointest Surg (2006) 0.75
Gastric DNA damage through tobacco chewing: in vitro mechanistic studies of DNA nitrite attack. Cancer Lett (2005) 0.75
Significant hypomagnesemia after celiotomy: implications of preoperative bowel cleansing with sodium phosphate purgative. Surgery (2002) 0.75
Image of the month--giant multicystic lymphangioma. Arch Surg (2005) 0.75